1-tert-butyloxycarbonyl-3-formylpyrrolo[3,2-c]pyridine | 877060-55-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 1-tert-butyloxycarbonyl-3-formylpyrrolo[3,2-c]pyridine
• 英文别名: tert-butyl 3-formyl-1H-pyrrolo[3,2-c]pyridine-1-carboxylate；3-formyl-pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester；tert-butyl 3-formylpyrrolo[3,2-c]pyridine-1-carboxylate
• CAS: 877060-55-4
• 化学式: C₁₃H₁₄N₂O₃
• 分子量: 246.266
• InChiKey: WDRSHMWGKULOGC-UHFFFAOYSA-N

物化性质

• 熔点：
  152-153 °C
• 沸点：
  402.0±48.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  61.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-tert-butyloxycarbonyl-3-formylpyrrolo[3,2-c]pyridine 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 5-氮杂吲哚-3-甲醛
  参考文献：
  名称：

  Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators

  摘要：

  Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance. IDO inhibition is thus an active area of research in drug development. Recently, our group has shown that tryptophan 2,3-dioxygenase (TDO), an unrelated hepatic enzyme also catalyzing the first step of tryptophan degradation, is also expressed in many tumors and that this expression prevents tumor rejection by locally depleting tryptophan. Herein, we report a structure- activity study on a series of 3-(2-(pyridyl)ethenyl)indoles. More than 70 novel derivatives were synthesized, and their TDO inhibitory potency was evaluated. The rationalization of the structure-activity relationships (SARs) revealed essential features to attain high TDO inhibition and notably a dense H-bond network mainly involving His(55) and Thr(254) residues. Our study led to the identification of a very promising compound (58) displaying good TDO inhibition (K-i = 5.5 mu M), high selectivity, and good oral bioavailability. Indeed, 58 was chosen for preclinical evaluation.

  DOI：

  10.1021/jm2006782
• 作为产物：
  描述：

  5-氮杂吲哚 在 4-二甲氨基吡啶 、 aluminum (III) chloride 作用下， 以 硝基甲烷 、 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 1.0h， 生成 1-tert-butyloxycarbonyl-3-formylpyrrolo[3,2-c]pyridine
  参考文献：
  名称：

  [EN] VIRAL REPLICATION INHIBITORS
  [FR] INHIBITEURS DE REPLICATION VIRALE

  摘要：

  本发明涉及一系列新化合物，通过使用这些新化合物来预防或治疗动物的病毒感染的方法，以及将这些新化合物用作药物，更好地用于治疗或预防病毒感染，特别是感染RNA病毒，更特别是感染属于黄病毒科的病毒，更特别是感染登革病毒。本发明还涉及这些新化合物的药物组合或混合制剂，用作药物的组合或制剂，更好地用于预防或治疗病毒感染。该发明还涉及这些化合物的制备方法。

  公开号：

  WO2013045516A1

文献信息

• Versatile and Convenient Methods for the Synthesis of C-2 and C-3 Functionalised 5-Azaindoles
  作者：Jean-Yves Mérour、Gérard Coudert、Myriam Lefoix、Jean-Philippe Daillant、Sylvain Routier、Isabelle Gillaizeau

  DOI：10.1055/s-2005-916028

  日期：——

  Functionalisation at C-2 and C-3 of N-protected-5-azaindole leads to a variety of very useful new substituted 5-azaindole derivatives in fair to good yields.

  N-protected-5-azaindole 的 C-2 和 C-3 官能化产生了多种非常有用的新取代 5-azaindole 衍生物，产率相当高。
• VIRAL REPLICATION INHIBITORS
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D

  公开号：US20140213586A1

  公开（公告）日：2014-07-31

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新化合物，使用这些新化合物预防或治疗动物的病毒感染的方法，以及这些新化合物的药物用途，更好地用于治疗或预防病毒感染，特别是RNA病毒感染，更特别是属于黄病毒科的病毒感染，更进一步地是登革热病毒感染。本发明还涉及新化合物的药物组成物或复合制剂，以及用于预防或治疗病毒感染的药物组成物或制剂。本发明还涉及化合物的制备方法。
• Viral replication inhibitors
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. Leuven R&D

  公开号：US10550123B2

  公开（公告）日：2020-02-04

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新型化合物、使用这些新型化合物预防或治疗动物病毒感染的方法以及用作药物的所述新型化合物，更优选用作治疗或预防病毒感染的药物，特别是 RNA 病毒感染，更特别是属于黄病毒科的病毒感染，更特别是登革热病毒感染。本发明还涉及新型化合物的药物组合物或组合制剂、用作药物的组合物或制剂，更优选用于预防或治疗病毒感染。本发明还涉及化合物的制备工艺。